Merck Preps for End of Keytruda Exclusivity with $6.7B Deal for Leukemia Treatment

What: Merck is preparing for the loss of exclusivity for its key cancer treatment Keytruda by acquiring a leukemia treatment for $6.7 billion.
Why: The deal aims to expand Merck's portfolio and maintain market share in the face of increasing competition.
Signal: The acquisition signals a shift in Merck's strategy to focus on emerging treatments and diversify its product lineup.
Target: The company is targeting a significant increase in revenue from its oncology division, driven by the new leukemia treatment and other emerging therapies.
Risk: The deal carries a risk of regulatory hurdles and potential competition from other companies developing similar treatments.